PHVS ▼ -3.2% - Pharvaris N.V.
$PHVS - Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
08-OCT-2026 06:35 PM ET
Share this post
More filings for $PHVS
PHVS ▲ +16.9% - Pharvaris N.V.Sep 8, 2026PHVS ▲ +16.9% - Pharvaris N.V.Sep 8, 2026PHVS ▲ +2.4% - Pharvaris N.V.Sep 3, 2026PHVS - Pharvaris N.V. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 15, 2026$PHVS SEC Filing Update (31-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 31, 2026
View full $PHVS filing history →💬 Comments
Loading comments…
Leave a comment